13472-59-8

Basic information

• Product Name: 3-Bromo-2-methoxypyridine
• Synonyms: 3-BROMO-2-METHOXYPYRIDINE;3-BROWN-2-METHOXYPYRIDINE;2-METHOXY-3-BROMOPYRIDINE;3-BROMO-2-METHOXYPYRIDINE ,98%;3-BroMo-2-Methoxypyridine, 95+%;Pyridine, 3-bromo-2-methoxy-
• CAS NO: 13472-59-8
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02
• EINECS: 1533716-785-6
• Product Categories: blocks;Bromides;Pyridines;Pyridine;Boronic Acid;C6Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridine Series;Heterocycle-Pyridine series
• Mol File: 13472-59-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 190.387 °C at 760 mmHg
• Flash Point: 93 °C
• Appearance: /
• Density: 1.5856
• Vapor Pressure: 0.752mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: Store under inert gas
• PKA: 1.04±0.10(Predicted)
• Water Solubility: Not miscible or difficult to mix in water.
• Sensitive: Moisture Sensitive/Light Sensi
• CAS DataBase Reference: 3-Bromo-2-methoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-2-methoxypyridine(13472-59-8)
• EPA Substance Registry System: 3-Bromo-2-methoxypyridine(13472-59-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 13472-59-8(Hazardous Substances Data)

Usage

Description

3-Bromo-2-methoxypyridine is an organic compound with the molecular formula C6H6BrNO. It is a derivative of pyridine, a heterocyclic compound with a six-membered ring and one nitrogen atom. The presence of a bromine atom at the 3rd position and a methoxy group at the 2nd position gives this compound unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
3-Bromo-2-methoxypyridine is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for further functionalization and modification, making it a valuable building block in the development of new drugs.
Used in Organic Synthesis:
3-Bromo-2-methoxypyridine is used as a key reactant in the facile synthesis of 2-unsubstituted benzofuran-3-carboxylates using diazo(trimethylsilyl)methyl magnesium bromide. This application highlights its utility in organic chemistry, particularly in the construction of complex molecular structures.
Used in Chemical Research:
Due to its unique structural features, 3-Bromo-2-methoxypyridine is also used in academic and industrial research settings to study various chemical reactions and mechanisms. It can serve as a model compound for understanding the reactivity of similar pyridine derivatives and their potential applications in various fields.

InChI:InChI=1/C6H6BrNO/c1-9-6-5(7)3-2-4-8-6/h2-4H,1H3

Upstream product

• 13466-43-8 3-bromopyridin-2(1H)-one 
• 74-88-4 methyl iodide 
• 1628-89-3 2-methoxypyridine 
• 52200-48-3 3-bromo-2-chloropyridine 
• 16498-81-0 2-methoxynicotinic acid 
• 124-41-4 sodium methylate 
• 13466-43-8 3-bromo-pyridin-2-ol 

Downstream Products

• 163105-90-6 2-methoxypyridin-3-yl-boronic acid 
• 160590-38-5 3-hydrazinyl-2-methoxypyridine 
• 532391-31-4 2-methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridine 
• 118006-02-3 (2-methoxypyridin-3-yl)(phenyl)methanol 

Relevant articles and documents

6 - Oxo -1, 6 - dihydropyridine derivative. Preparation method and application thereof in medicine

The invention relates to 6 - oxo -1, 6 - dihydropyridine derivatives, a preparation method and an application thereof in medicine. , The present disclosure relates to I oxo 6 -1 dihydropyridine derivatives represented by the general formula (6 -), a prepa

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Nonpeptide αvβ3 Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent αvβ3 Antagonist for the Prevention and Treatment of Osteoporosis

3(S)-(6-Methoxypyridin-3-yl)-3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8] -naphthyridin-2-yl)propyl]-imidazolidin-1-yl}propionic acid 6 was identified as a potent and selective antagonist of the αvβ3 receptor. This compound has an excellent in vitro profile (IC50 = 0.08 nM), a significant unbound fraction in human plasma (12%), and good pharmacokinetics in rat, dog, and rhesus monkey. On the basis of the efficacy shown in three in vivo models of bone turnover, the compound was selected for clinical development. To support the ongoing metabolism and safety studies, a novel strategy was employed in which a series of oxidized derivatives of 6 were prepared by exposure of 6 (or the methyl ester) to chemical oxidizing agents. These products proved useful in the identification of active metabolites generated by either in vitro or in vivo metabolism.